WallStSmart

Cytosorbents Crp (CTSO)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 56295% more annual revenue ($20.98B vs $37.20M). GEHC leads profitability with a 9.1% profit margin vs -31.9%. GEHC earns a higher WallStSmart Score of 57/100 (C).

CTSO

Avoid

24

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 3.5
Piotroski: 4/9Altman Z: -9.11

GEHC

Buy

57

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTSO0 strengths · Avg: 0/10

No standout strengths identified

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

Areas to Watch

CTSO4 concerns · Avg: 3.8/10
Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$22.75M3/10

Smaller company, higher risk/reward

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.834/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-30.9%2/10

Earnings declined 30.9%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CTSO

CTSO has a balanced fundamental profile.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : CTSO

The primary concerns for CTSO are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 8.64 is elevated, increasing financial risk.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

CTSO profiles as a turnaround stock while GEHC is a value play — different risk/reward profiles.

CTSO carries more volatility with a beta of 1.36 — expect wider price swings.

GEHC is growing revenue faster at 7.4% — sustainability is the question.

GEHC generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (57/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cytosorbents Crp

HEALTHCARE · MEDICAL DEVICES · USA

Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?